References
- Pappas G, Hadden W C, Kozak L J, Fisher G F. Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups. Am J Public Health 1997; 87(5):811–816. [PUBMED], [INFOTRIEVE], [CSA]
- Gergen P J, Weiss K B. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990; 264(13):1688–1692. [PUBMED], [INFOTRIEVE]
- Wissow L S, Gittelsohn A M, Szklo M, Starfield B, Mussman M. Poverty, race, and hospitalization for childhood asthma. Am J Public Health 1988; 78(7):777–782. [PUBMED], [INFOTRIEVE], [CSA]
- Carr W, Zeitel L, Weiss K. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health 1992; 82(1):59–65. [PUBMED], [INFOTRIEVE], [CSA]
- Lozano P, Connell F A, Koepsell T D. Use of health services by African–American children with asthma on Medicaid. JAMA 1995; 274(6):469–473. [PUBMED], [INFOTRIEVE]
- Balkrishnan R, Norwood G J, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin Ther 1998; 20(3):567–580. [PUBMED], [INFOTRIEVE], [CSA]
- Balkrishnan R, Norwood G J, Anderson A. Outcomes and cost benefit associated with introduction of inhaled corticosteroid therapy in a medicaid enrolled asthmatic children. Drug Benefit Trends 1998; 10(10):37–40.
- Smith M J, Rascati K L, Johnsrud M T. Costs and utilization patterns associated with persistent asthma. A comparison of Texas Medicaid patients with and without continuous inhaled corticosteroid treatment. J Manag Care Pharm 2001; 7(6):452–459.
- Stempel D A. Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. Respir Med 2001; 95:992–998. [PUBMED], [INFOTRIEVE], [CSA]
- Stempel D A, Meyer J W, Stanford R H, Yancey S W. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001; 107:94–98. [PUBMED], [INFOTRIEVE], [CSA]
- Stempel D A, Mauskopf J, McLaughlin T, Yazdani C, Stanford R H. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227–234. [PUBMED], [INFOTRIEVE], [CSA]
- Stempel D A, O'Donnell J C, Meyer J W. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109:433–439. [PUBMED], [INFOTRIEVE], [CSA]
- Bukstein D A, Henk H J, Luskin A T. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001; 23(9):1589–1600. [PUBMED], [INFOTRIEVE], [CSA]
- Price D B, Ben-Joseph R H, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir Med 2001; 95(1):83–89. [PUBMED], [INFOTRIEVE], [CSA]
- Edwards L D, Kral K M, Johnson J R, Lincourt W R. A retrospective descriptive medical claims analysis of increased medical risk in asthma management for patients prescribed montelukast compared to fluticasone propionate [abstract 1070]. J Allergy Clin Immunol 2001; 107(2):S329.
- Pathak D S, Davis E A, Stanford R H. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002; 22(2):166–174. [PUBMED], [INFOTRIEVE], [CSA]
- Spahn J, Covar R, Stempel D A. Asthma: addressing consistency in results from basic science, clinical trials and observational experience. J Allergy Clin Immunol 2002; 109:S490–S502. [PUBMED], [INFOTRIEVE], [CSA]
- Stempel D A, Kelly H W. Approaching value in asthma management: the need to intergrate clinical and economic research with the basic science. J Allergy Clin Immunol 2002; 109:S503–S510. [PUBMED], [INFOTRIEVE], [CSA]
- Laumann J M, Bjornson D C. Treatment of Medicaid patients with asthma: comparison with treatment guidelines using disease-based drug utilization review methodology. Ann Pharmacother 1998; 32(12):1290–1294. [PUBMED], [INFOTRIEVE], [CSA]
- Balkrishnan R, Christensen D B. A comparison of medication adherence indices to assess long-term inhaled corticosteroid medication use. J Asthma 2001; 38(1):91–98. [PUBMED], [INFOTRIEVE]
- Balkrishnan R, Byerly W G, Camacho F T, Shrestha A, Anderson R T. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population. Am J Manag Care 2001; 7(11):1093–1100. [PUBMED], [INFOTRIEVE], [CSA]
- Stempel D A, Mauskopf J, McLaughlin T, Yazdani C, Stanford R H. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227–234. [PUBMED], [INFOTRIEVE], [CSA]
- Farber H J, Capra A M, Finkelstein J A, Lozano P, Quesenberry C P, Jensvold N G, Chi F W, Lieu T A. Misunderstanding of asthma controller medications: association with nonadherence. J Asthma 2003; 40(1):17–25. [PUBMED], [INFOTRIEVE]
- Balkrishnan R, Christensen D B. Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments. J Asthma 2000; 37(6):511–517. [PUBMED], [INFOTRIEVE]